无严重OSA的肥胖低通气综合征长期无创通气:Pickwick随机对照试验
这项在西班牙16个中心开展的多中心、开放标签、平行组随机对照试验纳入98例未治疗的无严重OSA(AHI<30次/小时)的稳定门诊OHS患者,随机分为NIV组或生活方式干预组。中位随访4.98年,主要终点每年住院天数两组相似(对照组2.60±5.31天 vs NIV组2.71±4.52天;校正率比1.07;95%CI 0.44-2.59;P=0.882)。NIV组在PaCO2、pH、碳酸氢盐、生活质量(SF-36躯体成分)和日间嗜睡方面有显著纵向改善;按方案分析显示NIV组首次急诊就诊时间有统计学显著差异;高依从性亚组首次住院、急诊就诊和死亡时间较低依从性亚组更长。两臂不良事件相似。
要点
- 无严重OSA的OHS患者中,NIV与生活方式干预的每年住院天数相似(对照组2.60±5.31天 vs NIV组2.71±4.52天;校正率比1.07;95%CI 0.44-2.59;P=0.882)。
- NIV组较对照组在PaCO2、pH、碳酸氢盐、生活质量(SF-36躯体成分)和日间嗜睡方面有显著纵向改善。
- 按方案分析显示NIV组首次急诊就诊时间有统计学显著差异,优于对照组。
- 高NIV依从性亚组首次住院、急诊就诊和死亡时间较低依从性亚组更长。
- 两臂不良事件相似;研究因难以识别无严重OSA的OHS患者而在第8年提前终止。
适用人群与场景
- 西班牙16个中心招募的稳定门诊OHS患者,未治疗,呼吸暂停低通气指数<30次/小时(即无严重OSA)。
诊断标准与关键阈值
- OHS诊断依据原文未详述;纳入标准为呼吸暂停低通气指数<30次/小时(无严重OSA)。
处置流程与药物剂量
- NIV组接受无创通气治疗;对照组接受生活方式干预;原文未给出具体NIV参数、模式、压力设置或生活方式干预细节。
研究设计与关键结果
- 多中心、开放标签、平行组随机对照试验,98例随机(NIV组49例,对照组49例),每组48例纳入分析;中位随访4.98年(四分位距2.98-6.62)。
- 主要终点每年住院天数:对照组2.60±5.31天 vs NIV组2.71±4.52天(校正率比1.07;95%CI 0.44-2.59;P=0.882),无统计学显著差异。
- NIV组较对照组在PaCO2、pH、碳酸氢盐、生活质量(SF-36躯体成分)和日间嗜睡方面有显著纵向改善。
- 按方案分析显示NIV组首次急诊就诊时间有统计学显著差异,优于对照组。
- 高NIV依从性亚组首次住院、急诊就诊和死亡时间较低依从性亚组更长。
- 两臂不良事件相似。
证据类型、等级与局限
- 证据类型:多中心、开放标签、平行组随机对照试验(RCT)。
- 研究因难以识别无严重OSA的OHS患者而在第8年提前终止。
- 局限:研究提前终止;作者指出需要更大规模的研究来更好地确定NIV在该OHS亚组中的长期获益。
对床旁实践的改变
- 对于无严重OSA的稳定门诊OHS患者,NIV与生活方式干预在长期住院天数上相似,但NIV可改善血气、生活质量和日间嗜睡。
- 作者认为,旨在提高NIV依从性的更强化方案可能带来更好结局。
指南或共识出处
- ClinicalTrials.gov注册号NCT01405976。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Noninvasive ventilation (NIV) is an effective form of treatment in obesity hypoventilation syndrome (OHS) with severe OSA. However, there is paucity of evidence in patients with OHS without severe OSA phenotype.
RESEARCH QUESTION: Is NIV effective in OHS without severe OSA phenotype?
STUDY DESIGN AND METHODS: In this multicenter, open-label parallel group clinical trial performed at 16 sites in Spain, we randomly assigned 98 stable ambulatory patients with untreated OHS and apnea-hypopnea index < 30 events/h (ie, no severe OSA) to NIV or lifestyle modification (control group) using simple randomization through an electronic database. The primary end point was hospitalization days per year. Secondary end points included other hospital resource utilization, incident cardiovascular events, mortality, respiratory functional tests, BP, quality of life, sleepiness, and other clinical symptoms. Both investigators and patients were aware of the treatment allocation; however, treating physicians from the routine care team were not aware of patients' enrollment in the clinical trial. The study was stopped early in its eighth year because of difficulty identifying patients with OHS without severe OSA. The analysis was performed according to intention-to-treat and per-protocol principles and by adherence subgroups.
RESULTS: Forty-nine patients in the NIV group and 49 in the control group were randomized, and 48 patients in each group were analyzed. During a median follow-up of 4.98 years (interquartile range, 2.98-6.62), the mean hospitalization days per year ± SD was 2.60 ± 5.31 in the control group and 2.71 ± 4.52 in the NIV group (adjusted rate ratio, 1.07; 95% CI, 0.44-2.59; P = .882). NIV therapy, in contrast with the control group, produced significant longitudinal improvement in Paco2, pH, bicarbonate, quality of life (Medical Outcome Survey Short Form 36 physical component), and daytime sleepiness. Moreover, per-protocol analysis showed a statistically significant difference for the time until the first ED visit favoring NIV. In the subgroup with high NIV adherence, the time until the first event of hospital admission, ED visit, and mortality was longer than in the low adherence subgroup. Adverse events were similar between arms.
INTERPRETATION: In stable ambulatory patients with OHS without severe OSA, NIV and lifestyle modification had similar long-term hospitalization days per year. A more intensive program aimed at improving NIV adherence may lead to better outcomes. Larger studies are necessary to better determine the long-term benefit of NIV in this subgroup of OHS.
TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT01405976; URL: www.clinicaltrials.gov.
参考来源
- Masa JF, Benítez I, Sánchez-Quiroga MÁ, et al. Long-term Noninvasive Ventilation in Obesity Hypoventilation Syndrome Without Severe OSA: The Pickwick Randomized Controlled Trial. Chest. 2020. PMID: 32343963. doi:10.1016/j.chest.2020.03.068
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。